Harvard Bioscience, Inc. (HBIO) |
| 6.23 0.28 (4.71%) 07-17 16:00 |
| Open: | 5.96 |
| High: | 6.3206 |
| Low: | 5.95 |
| Volume: | 14,399 |
| Market Cap: | 28(M) |
| PE Ratio: | -17.31 |
| Exchange: | NASDAQ |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 6.72 |
| Resistance 1: | 6.36 |
| Pivot price: | 6.16 |
| Support 1: | 5.77 |
| Support 2: | 4.80 |
| 52w High: | 9.4 |
| 52w Low: | 3.8 |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
| EPS | -2.150 |
| Book Value | 2.230 |
| PEG Ratio | 1.31 |
| Gross Profit | 11.080 |
| Profit Margin (%) | -11.44 |
| Operating Margin (%) | -4.52 |
| Return on Assets (ttm) | 1.7 |
| Return on Equity (ttm) | -78.7 |
Fri, 10 Jul 2026
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Thu, 25 Jun 2026
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 27 May 2026
HBIO - Harvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Thu, 14 May 2026
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Tue, 12 May 2026
HARVARD BIOSCIENCE ($HBIO) Releases Q1 2026 Earnings - Quiver Quantitative
Tue, 12 May 2026
Harvard Bioscience Announces First Quarter 2026 Financial Results - GlobeNewswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |